ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0231796 | null | null | respiratory abnormalities |
C1279087 | null | Entire ulna (body structure)|Entire ulna | Entire ulna |
C0230329 | null | Right upper extremity|Right upper extremity structure|Right upper limb|Right forelimb|Structure of right upper limb|Structure of right upper limb (body structure) | Right upper extremity |
C0029458 | Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency. | Post-Menopausal Osteoporoses|Postmenopausal osteoporosis|OSTEOPOROSIS, POSTMENOPAUSAL|osteoporosis post menopausal|osteoporosis postmenopausal|Perimenopausal Bone Losses|Postmenopausal osteoporosis (disorder)|Postmenopausal Bone Losses|Postmenopausal Osteoporoses|Postmenopausal Bone Loss|type i osteoporosis|Osteoporosis, Post Menopausal|Bone Losses, Perimenopausal|Bone Loss, Perimenopausal|Menopausal osteoporosis (disorder)|Osteoporosis, Postmenopausal|Type 1 osteoporosis|Osteoporoses, Postmenopausal|post menopausal osteoporosis|Bone Losses, Postmenopausal|Menopausal osteoporosis|Bone Loss, Postmenopausal|Perimenopausal Bone Loss|postmenopausal osteoporosis|Postmenopausal Osteoporosis|postmenopausal bone loss|bone loss postmenopausal|Osteoporoses, Post-Menopausal|Post-Menopausal Osteoporosis|Type I osteoporosis|menopausal osteoporosis post|Osteoporosis, Post-Menopausal | Osteoporosis, Postmenopausal |
C0007439 | Catheters designed to be left within an organ or passage for an extended period of time. | In-Dwelling Catheter|Catheters, In-Dwelling|Catheter, In-Dwelling|indwelling catheter|Indwelling Catheters|indwelling catheters|In Dwelling Catheters|venous reservoir|Indwelling Catheter|Catheter, Indwelling|In-Dwelling Catheters|catheters indwelling|catheter indwelling|Catheters, Indwelling | Indwelling Catheter |
C0007439 | Catheters designed to be left within an organ or passage for an extended period of time. | In-Dwelling Catheter|Catheters, In-Dwelling|Catheter, In-Dwelling|indwelling catheter|Indwelling Catheters|indwelling catheters|In Dwelling Catheters|venous reservoir|Indwelling Catheter|Catheter, Indwelling|In-Dwelling Catheters|catheters indwelling|catheter indwelling|Catheters, Indwelling | Indwelling Catheter |
C0011212 | Hospital units equipped for childbirth. | Delivery suite (environment)|Centers, Hospital Birthing|birth centers hospitals|Centers, Hospital Birth|Delivery room|Room, Delivery|Hospital Birthing Centers|Birth Center, Hospital|Delivery Room|Hospital Birth Center|Birth Centers, Hospital|Birthing Center, Hospital|Center, Hospital Birthing|Rooms, Delivery|Center, Hospital Birth|Birthing Centers, Hospital|Delivery suite|Hospital Birth Centers|Hospital Birthing Center|delivery room|delivery rooms | Delivery Rooms |
C0020672 | Lower than normal body temperature, especially in warm-blooded animals. | Hypothermia (finding)|hypothermic|below normal body temperature|TEMPERATURE BODY DECREASE|BODY TEMPERATURE DECREASED|State of hypothermia|hypothermia|low body temperature|Hypothermic|Decreased body temperature|Hypothermia|Temperature, Decreased Body|Body Temperature, Decreased|Decreased Body Temperature|body temperature low|decreased body temperature|HYPOPYREXIA|Body temperature below normal|subnormal temperature|HYPOTHERMIA|Body temperature, decreased|Temperature subnormal|Decreased Core Body Temperature|subnormal temperatures|body temperature below normal|Abnormally low body temperature|Hypothermias|BODY TEMPERATURE LOW | Hypothermia, natural |
C0005615 | The process of giving birth to one or more offspring. | parturitions|Parturitions|Births|childbirth|Birth (finding)|Birth, NOS|Parturition|births|Parturition, NOS|parturition|birth|Giving birth|giving birth|Birth | Birth |
C0032740 | null | Positive End Expiratory Pressure|End-Expiratory Pressure, Positive|Pressures, Positive End-Expiratory|Pressure, Positive End-Expiratory|peep|positive end expiratory pressure|positive end expiratory pressure (PEEP)|positive end-expiratory pressure|Positive End-Expiratory Pressure|Positive End-Expiratory Pressures|End-Expiratory Pressures, Positive|positive pressure breathing|peeps | Positive End-Expiratory Pressure |
C0002638 | A clear, yellowish liquid that envelopes the FETUS inside the sac of AMNION. In the first trimester, it is likely a transudate of maternal or fetal plasma. In the second trimester, amniotic fluid derives primarily from fetal lung and kidney. Cells or substances in this fluid can be removed for prenatal diagnostic tests (AMNIOCENTESIS). | Waters (Amniotic Fluid)|Human Amniotic Fluid|Liquor Amnii|AMNIOTIC FLUID|Fluid, Amniotic|Liquor|AF - Amniotic fluid|liquor|Aqua Amnii|Amniotic Fluids|FLUID, AMNIOTIC|Amniotic Fluid|Amniotic fluid|Fluids, Amniotic|amniotic fluid|amniotic fluids|Amniotic fluid (substance) | Amniotic Fluid |
C0038638 | The removal of secretions, gas or fluid from hollow or tubular organs or cavities by means of a tube and a device that acts on negative pressure. | Suction drainage|Suction|suctioning|Suction Drainage|Aspirations, Mechanical|Suctions|Suction drainage (procedure)|Aspiration, Mechanical|Suction Procedure|Mechanical Aspirations|suction|Suction Drainages|Drainages, Suction|Mechanical Aspiration|Drainage, Suction | Suction drainage |
C0199451 | A form of non-invasive mechanical pressure support ventilation that uses a continuous positive airway pressure level to support spontaneous breathing activity. | CPAP (continuous positive airway pressure)|CPAP - Continuous positive airways pressure|CPAP|CPAP - Continuous positive airways pressure therapy|CPAP Ventilation|Ventilation, CPAP|Continuous positive airway pressure (CPAP)|CPAP treatment|continuous positive airway pressure|continuous positive airway pressure (CPAP)|Continuous positive airway pressure ventilation treatment (regime/therapy)|Continuous positive airways pressure therapy|cpap treatment|Continuous Positive Airway Pressure|Continuous positive airway pressure ventilation treatment|cpap ventilation | Continuous Positive Airway Pressure |
C0021778 | Application of positive pressure to the inspiratory phase when the patient has an artificial airway in place and is connected to a ventilator. | Intermittent Positive-Pressure Ventilation|IPPV - intermittent positive pressure ventilation|ventilation pressure positive|Inspiratory Positive Pressure Ventilation|Ventilation, Intermittent Positive-Pressure|Intermittent Positive Pressure Ventilation|Positive pressure ventilation|positive pressure ventilation|Ventilation, Inspiratory Positive-Pressure|ippv|Intermittent positive pressure ventilation|PPV - Positive pressure ventilation|Inspiratory Positive-Pressure Ventilation|Intermittent positive pressure ventilation (procedure)|intermittent positive pressure ventilation|Positive-Pressure Ventilation, Intermittent|IPPV|Positive-Pressure Ventilation, Inspiratory|Ventilation, Intermittent Positive Pressure | Intermittent Positive-Pressure Ventilation |
C0162645 | A type of oropharyngeal airway that provides an alternative to endotracheal intubation and standard mask anesthesia in certain patients. It is introduced into the hypopharynx to form a seal around the larynx thus permitting spontaneous or positive pressure ventilation without penetration of the larynx or esophagus. It is used in place of a facemask in routine anesthesia. The advantages over standard mask anesthesia are better airway control, minimal anesthetic gas leakage, a secure airway during patient transport to the recovery area, and minimal postoperative problems. | Mask, Laryngeal|Laryngeal Mask Airway|Masks, Laryngeal|Laryngeal Mask|Laryngeal Mask Airways|Airway, Laryngeal Mask|LMA - Laryngeal mask airway|laryngeal masks|LMA|Laryngeal mask|laryngeal mask|Airways, Laryngeal Mask|Laryngeal mask (physical object)|laryngeal mask airway|Laryngeal Masks | Laryngeal Masks |
C0359180 | null | Albumin solution (product)|Human albumin solution|albumin solution|Human albumin solution (product) | Albumin solution |
C0014563 | The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS. | Epinephrine-containing product|(R)-(-)-Epirenamine|(R)-(-)-adrenaline|Epinephrine|Adrenaline-containing product|Epinephrin|(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol|epi|Epinefrin|Adrenal|Therapeutic Epinephrine|therapeutic epinephrine|(R)-(-)-Epinephrine|Epinephrinum|Adrenaline preparation|4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol|Product containing epinephrine (medicinal product)|(R)-(-)-Adrenaline|epinephrine|EPINEPHRINE|EPINEPHrine|Adrénaline|(-)-(R)-epinephrine|(R)-(-)-Adnephrine|Epinephrine preparation|Adrenalin|Adrenaline|Epinephrine (substance)|adrenalin|Epi|Epinefrina|1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (R)-|4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol|adrenaline | epinephrine |
C0678856 | null | skilled|skills | skill |
C0701159 | null | hospitalized|HOSPITALIZED|hospitalize|hospitalizes|Patient in hospital (finding)|patient in hospital | Patient in hospital |
C0036974 | A pathological condition manifested by failure to perfuse or oxygenate vital organs. | CARDIOVASCULAR COLLAPSE|COLLAPSE CARDIOVASCULAR|SHOCK CIRCULATORY|SHOCK VASCULAR|circulatory collapse|Circulatory shock|shocked|COLLAPSE CIRCULATORY|Acute peripheral circulatory failure|Peripheral vascular failure|circulatory failure|shock|Collapse, Circulatory|cardiovascular collapse|physiological shock|COLLAPSE PERIPHERAL VASCULAR|COLLAPSE PERIPHERAL CIRCULATORY|Failure of peripheral circulation|CIRCULATORY COLLAPSE|CIRCULATORY FAILURE|acute circulatory failure|Shock - physiological|Shock (disorder)|disorders shock|shock disorder|Failure, Circulatory|Circulatory collapse|circulatory shock|COLLAPSE VASCULAR|FAILURE PERIPHERAL CIRCULATORY|Acute circulatory failure|Vascular collapse|collapse|FAILURE CIRCULATORY|shock syndrome|Circulatory Collapse|Shock|Shock, NOS|Circulatory failure|VASCULAR COLLAPSE|shock, physiological|vascular collapse|Circulatory Failure|Peripheral vascular shutdown|Peripheral circulatory failure|Shock, unspecified|SHOCK SYNDROME|shocks|shocking|vascular shock|SHOCK | Shock |
C0004044 | A pathological condition caused by lack of oxygen, manifested in impending or actual cessation of life. | Suffocation, NOS|Asphyxia|Suffocations|Asphyxiation (event)|Asphyxiation|suffocating|Asphyxias|ASPHYXIA|Suffocation|suffocations|Asphyxiation, NOS|suffocate|suffocation|asphyxia|asphyxias|asphyxiation|Suffocating|Suffocating (finding) | Asphyxia |
C1449855 | null | Nuchal translucency|folds nuchal|Nuchal Fold|Translucency, Nuchal|nuchal fold | Nuchal Translucency |
C0392053 | The occurrence of 2 or more cell lines with different genetic or chromosomal make-up, within a single individual or tissue. | MOSAICISM|Mosaicism (morphologic abnormality)|Mosaicism, NOS|Mosaicism|mosaicism|disorders mosaicism | Embryonic Mosaic |
C0002627 | Percutaneous transabdominal puncture of the uterus during pregnancy to obtain amniotic fluid. It is commonly used for fetal karyotype determination in order to diagnose abnormal fetal conditions. | Amniocenteses|amniocenteses|amniocentesis|Amniocentesis (procedure)|amniotic fluid test (AFT)|Diagnostic amniocentesis|Amniocentesis, NOS|Amniocentesis|Incision and drainage of amnion|AC - Amniocentesis|Diagnostic amniocentesis (procedure)|amniocentesis procedure | Amniocentesis |
C1273723 | null | brain region|brain regions|Brain region (body structure) | Brain region |
C0033164 | Small proteinaceous infectious particles which resist inactivation by procedures that modify NUCLEIC ACIDS and contain an abnormal isoform of a cellular protein which is a major and necessary component. The abnormal (scrapie) isoform is PrPSc (PRPSC PROTEINS) and the cellular isoform PrPC (PRPC PROTEINS). The primary amino acid sequence of the two isoforms is identical. Human diseases caused by prions include CREUTZFELDT-JAKOB SYNDROME; GERSTMANN-STRAUSSLER SYNDROME; and INSOMNIA, FATAL FAMILIAL. | prion|prion protein|Prions|prions|Proteinaceous infectious particle|Prion, NOS|Prion|Prion protein|Pr P|Prion (organism)|prion proteins | Prions |
C0006462 | An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM. | 8-Azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-|Buspiron|BUSPIRONE|Buspirona|Product containing buspirone (medicinal product)|buspirone|Buspirone (substance)|N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide|Buspironum|Buspirone-containing product|8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione|busPIRone|Buspirone | buspirone |
C0006462 | An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM. | 8-Azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-|Buspiron|BUSPIRONE|Buspirona|Product containing buspirone (medicinal product)|buspirone|Buspirone (substance)|N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide|Buspironum|Buspirone-containing product|8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione|busPIRone|Buspirone | buspirone |
C0379900 | A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN RECEPTOR AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION. | Receptor, 5-HT1A Serotonin|5-ht1a receptor|Serotonin 1A Receptor|Receptor, 5-Hydroxytryptamine 1A|5-HT1A Serotonin Receptor|Receptor, 5-HT1A|5-HT(1A) Receptor|5-Hydroxytryptamine 1A Receptor|Serotonin Receptor, 5 HT1A|Serotonin, 5 HT1a Receptor|Receptor, 5 Hydroxytryptamine 1A|1A Receptor, 5-Hydroxytryptamine|5-HT 1A receptor|5 HT1A Receptor|1A Receptors, 5-Hydroxytryptamine|5-Hydroxytryptamine 1A Receptors|serotonin 1a receptor|Receptor, Serotonin 1A|5-HT1A Receptor|5-hydroxytryptamine 1A receptor|5 Hydroxytryptamine 1A Receptors|5-HT1a Receptor Serotonin|Receptor, Serotonin, 5-HT1A|5 Hydroxytryptamine 1A Receptor|Serotonin Receptor, 5-HT1A|Receptor Serotonin, 5-HT1a|Receptors, 5-Hydroxytryptamine 1A|Serotonin, 5-HT1a Receptor | Receptor, Serotonin, 5-HT1A |
C0020431 | The therapeutic intermittent administration of oxygen in a chamber at greater than sea-level atmospheric pressures (three atmospheres). It is considered effective treatment for air and gas embolisms, smoke inhalation, acute carbon monoxide poisoning, caisson disease, clostridial gangrene, etc. (From Segen, Dictionary of Modern Medicine, 1992). The list of treatment modalities includes stroke. | oxygen hyperbaric therapy|Hyperbaric oxygen therapy|HOT - Hyperbaric oxygen therapy|Hyperbaric Treatment|Oxygenations, Hyperbaric|Hyperbaric Oxygenations|Hyperbaric Oxygen Therapies|Hyperbaric Oxygen Therapy|hyperbaric oxygenation|Hyperbaric Therapy|Therapies, Hyperbaric Oxygen|Therapy, Hyperbaric Oxygen|Hyperbaric Oxygenation|Oxygenation, Hyperbaric|Hyperbaric oxygen therapy (procedure)|Oxygen Therapies, Hyperbaric|Hyperbaric oxygenation|Oxygen Therapy, Hyperbaric|hyperbaric oxygen therapy | Hyperbaric oxygenation therapy |
C0098450 | null | null | 5-hydroxydecanoate |
C0028027 | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | NIACINAMIDE|b3 vitamin|Nicotinamida|nicotinamide|vitamin b3|Vitamin B 3|Nicotinamide (substance)|Nicotinic Acid Amide|vitamin b 3|3 Pyridinecarboxamide|Nicotinamidum|vitamin B3|b3 vitamins|niacinamide|Nicotinic acid amide|B 3, Vitamin|Niacinamide preparation|Nicotinamide preparation|B3, Vitamin|Niacinamide|β-pyridinecarboxamide|vitamin pp|3-Pyridinecarboxamide|3-pyridinecarboxamide|Nicotylamide|Vitamin PP|NIACIN (AS NIACINAMIDE)|Nicotinamide|Vitamin B3|Pellagra-Preventing Factor|vitamin PP|Nicotinic amide|VITAMIN B3 | niacinamide |
C0752304 | Ischemic brain damage in which the entire brain is deprived of oxygen. It may be fatal or lead to long term disabilities including developmental delays, intellectual disability, and seizures. | encephalopathy hypoxic-ischemic|Encephalopathy, Hypoxic-Ischemic|Hypoxic-ischemic encephalopathy (HIE)|Ischemic Hypoxic Encephalopathy|Encephalopathy, Ischemic-Hypoxic|Hypoxic-ischemic encephalopathy, unspecified|encephalopathy hypoxic ischemic|hypoxic ischemic encephalopathy|Hypoxic ischemic brain injury|Encephalopathies, Hypoxic-Ischemic|Encephalopathies, Ischemic-Hypoxic|Hypoxic ischemic encephalopathy|Hypoxic-ischemic encephalopathy (disorder)|HIE|Hypoxic-Ischemic Encephalopathies|Ischemic-Hypoxic Encephalopathies|Hypoxic-Ischemic Encephalopathy|Hypoxic ischemic encephalopathy (disorder)|Hypoxic ischaemic encephalopathy|Hypoxic ischaemic brain injury|hypoxic-ischemic encephalopathy|Anoxic encephalopathy|Hypoxic Ischemic Encephalopathy|hypoxic ischemic brain injury|Hypoxic-ischemic encephalopathy|Encephalopathy, Hypoxic Ischemic|Ischemic-Hypoxic Encephalopathy | Hypoxic-Ischemic Encephalopathy |
C0295541 | null | 15-F2t-IsoP|15-F(2t)-IsoP|15-F2t-isoprostane|8-F(2t)-isoprostane|8-iso-PGF(2alpha)|15-F(2t)-isoprostane|isoprostaglandin F2alpha type-III|8-isoprostane|8 isoprostane|8-iso-PGF2alpha | 8-isoprostaglandin F2alpha |
C0028027 | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | NIACINAMIDE|b3 vitamin|Nicotinamida|nicotinamide|vitamin b3|Vitamin B 3|Nicotinamide (substance)|Nicotinic Acid Amide|vitamin b 3|3 Pyridinecarboxamide|Nicotinamidum|vitamin B3|b3 vitamins|niacinamide|Nicotinic acid amide|B 3, Vitamin|Niacinamide preparation|Nicotinamide preparation|B3, Vitamin|Niacinamide|β-pyridinecarboxamide|vitamin pp|3-Pyridinecarboxamide|3-pyridinecarboxamide|Nicotylamide|Vitamin PP|NIACIN (AS NIACINAMIDE)|Nicotinamide|Vitamin B3|Pellagra-Preventing Factor|vitamin PP|Nicotinic amide|VITAMIN B3 | niacinamide |
C0394162 | Therapy for MOVEMENT DISORDERS, especially PARKINSON DISEASE, that applies electricity via stereotactic implantation of ELECTRODES in specific areas of the BRAIN such as the THALAMUS. The electrodes are attached to a neurostimulator placed subcutaneously. | deep brain stimulation|brain deep stimulation|Brain Stimulation, Deep|Deep brain stimulation (procedure)|Deep Brain Stimulation|Stimulations, Deep Brain|Stimulation, Deep Brain|Deep Brain Stimulations|Deep brain stimulation|Deep Brain Stimulation Therapy|DBS|Brain Stimulations, Deep|DBS - Deep brain stimulation | Deep Brain Stimulation |
C1281060 | null | null | Entire subthalamic nucleus |
C0205141 | Star shaped. | Stellate (qualifier value)|Stellate|stellate | Stellate |
C0205093 | Situated at or extending to the side. | Lateral (qualifier value)|LATERAL|lateral|Lateral | Lateral |
C0205098 | Toward the middle or inside (as opposed to lateral). | MEDIAL|Medial (qualifier value)|medial|Medial | Medial |
C0205146 | The extent of a 2-dimensional surface enclosed within a boundary. | areas|Area (qualifier value)|area|AREA|Area | Area |
C0035507 | The posterior of the three primitive cerebral vesicles of an embryonic brain. It consists of myelencephalon, metencephalon, and isthmus rhombencephali from which develop the major BRAIN STEM components, such as MEDULLA OBLONGATA from the myelencephalon, CEREBELLUM and PONS from the metencephalon, with the expanded cavity forming the FOURTH VENTRICLE. | hind brain|Brain, Hind|Hindbrain structure (body structure)|Rhombencephalon|Hindbrains|Hindbrain|Hind-Brain|rhombencephalon|Hind Brains|Rhombencephalons|Hindbrain structure|Brains, Hind|Hind Brain|hindbrain | hindbrain |
C0175505 | null | Lateral reticular nucleus|Nucleus reticularis lateralis|lateral reticular nuclei|Nucleus reticularis lateralis (medullae)|Lateral reticular nucleus (medulla)|Nucleus lateralis medullae oblongatae | lateral reticular nucleus (medulla) |
C0175518 | GRAY MATTER located in the dorsomedial part of the MEDULLA OBLONGATA associated with the solitary tract. The solitary nucleus receives inputs from most organ systems including the terminations of the facial, glossopharyngeal, and vagus nerves. It is a major coordinator of AUTONOMIC NERVOUS SYSTEM regulation of cardiovascular, respiratory, gustatory, gastrointestinal, and chemoreceptive aspects of HOMEOSTASIS. The solitary nucleus is also notable for the large number of NEUROTRANSMITTERS which are found therein. | Nucleus tractus solitarii|Structure of nucleus of tractus solitarius|Nucleus tracti solitarii|Nucleus fasciculus solitarius|Tractus Solitarius Nucleus|Nuclei Tractus Solitarii|Solitary Tract Nucleus|Solitary Nuclear Complices|Nucleus of the Tractus Solitarius|Nucleus of Solitary Tract|Nucleus of tractus solitarius|Nucleus Tractus Solitarii|Nucleus Solitarius|Nucleus solitarius|Nucleus of Tractus Solitarius|Tractus Solitarius, Nuclei|NTS|Nuclei of solitary tract|Solitarius, Nuclei Tractus|Nucleus, Solitary|Nucleus tractus solitarius|Complex, Solitary Nuclear|solitary tract nucleus|Complices, Solitary Nuclear|Nuclear Complex, Solitary|Nucleus of solitary tract|Tractus solitarius nucleus|Nucleus, Solitary Tract|Solitary tract nuclear complex|nucleus tractus solitarius|Structure of nucleus of tractus solitarius (body structure)|Solitary Nuclear Complex|Nuclei Tractus Solitarius|Nucleus of the Solitary Tract|Solitarius Nucleus, Tractus|Solitary nucleus|Solitary nuclei|Solitarii, Nuclei Tractus|Nucleus Tractus Solitarius|Tractus Solitarii, Nuclei|Nuclear Complices, Solitary|Solitary Nucleus | Nucleus solitarius |
C1281211 | null | Entire nucleus ambiguus (body structure)|Entire nucleus ambiguus | Entire nucleus ambiguus |
C0237795 | null | pressors|Pressors|pressor|drugs pressor | Pressors |
C0009950 | Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most commonly used as experimental tools. | convulsants|Convulsants|convulsant | Convulsants |
C0074414 | A fluorinated isopropyl ether with general anesthetic property. Although the mechanism of action has not been fully elucidated, sevoflurane may act by interfering with the release and re-uptake of neurotransmitters at post-synaptic terminals, and/or alter ionic conductance following receptor activation by a neurotransmitter. Sevoflurane may also interact directly with lipid matrix of neuronal membranes, thereby affecting gating properties of ion channels. In addition, this agent may activate gamma-aminobutyric acid (GABA) receptors hyperpolarizing cell membranes. This results in a general anesthetic effect, a decrease in myocardial contractility and mean arterial pressure as well as an increased respiratory rate. | Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-|Sevoflurane-containing product|SEVOFLURANE|Product containing sevoflurane (medicinal product)|Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl Ether|1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane|Ether, Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl-|Sevoflurane (substance)|Sevofluranum|sevoflurane|Sevofluran|Fluoromethyl Hexafluoroisopropyl Ether|Sevoflurane|Sevoflurano|Fluoromethyl 2,2,2-trifluoro-1-(trifluromethyl)ethyl ether | sevoflurane |
C0037080 | null | pathways signaling|Pathway, Signal|Pathways, Signal|pathway signaling|Signal Pathway|signal pathway | Signal Pathways |
C0024591 | Rapid and excessive rise of temperature accompanied by muscular rigidity following general anesthesia. | Hyperthermia of anaesthesia|Malignant hyperthermia due to anaesthesia|Anesthesia Related Hyperthermias|hyperpyrexia malignant|Malignant hyperpyrexia due to anaesthetic|Hyperthermias, Anesthesia Related|Malignant hyperpyrexia|Malignant Hyperthermias|malignant fever|Malignant hyperpyrexia caused by anaesthesia|Malignant Hyperpyrexia|MH - Malignant hyperpyrexia|Malignant hyperpyrexia caused by anesthetic (finding)|HYPERPYREXIA MALIGNANT|Malignant hyperthermia|Malignant hyperpyrexia caused by anesthesia|malignant hyperthemia|Malignant hyperthermia caused by anaesthesia|Hyperthermia of anesthesia|hyperthermia of anesthesia|Hyperthermia, Anesthesia Related|hyperthermia malignant|Hyperpyrexia, Malignant|HYPERTHERMIA, MALIGNANT|Hyperthermia of Anesthesia|Malignant Hyperthermia Syndrome|HYPERPYREXIA, FULMINATING|Anesthesia Related Hyperthermia|Related Hyperthermias, Anesthesia|Malignant hyperthermia (finding)|MHS - Malignant hyperthermia|malignant hyperthermia|MALIGNANT HYPERTHEMIA|Malignant hyperpyrexia due to anesthesia|Anesthesia Hyperthermias|MALIGNANT HYPERTHERMIA|Related Hyperthermia, Anesthesia|Malignant Hyperpyrexias|Hyperthermia, Malignant|Malignant hyperpyrexia due to anaesthesia|FEVER MALIGNANT|anesthesia related hyperthermia|Hyperpyrexias, Malignant|Malignant hyperthermia caused by anesthesia|HYPERTHERMIA MALIGNANT|Malignant hyperthermia with anesthesia|Malignant Hyperthermia|Malignant hyperpyrexia caused by anesthetic|Malignant hyperpyrexia due to anesthetic|Malignant hyperthermia due to anesthesia|malignant hyperpyrexia|Anesthesia Hyperthermia|Malignant hyperpyrexia caused by anaesthetic | Malignant hyperpyrexia due to anesthesia |
C0035983 | A methylpyrrole-carboxylate from RYANIA that disrupts the RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL to modify CALCIUM release from SARCOPLASMIC RETICULUM resulting in alteration of MUSCLE CONTRACTION. It was previously used in INSECTICIDES. It is used experimentally in conjunction with THAPSIGARGIN and other inhibitors of CALCIUM ATPASE uptake of calcium into SARCOPLASMIC RETICULUM. | Ryanodol, 3-(1H-pyrrole-2-carboxylate)|Ryanodine (substance)|Ryania|ryanodine|Ryanodine | Ryanodine |
C0666891 | null | XeD compound | xestospongin D |
C0049506 | A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders. | 6 Azamianserin|Mirtazapine|Mepirzapine|Mirtazapine-containing product|Mirtazapina|Mirtazapinum|6-Azamianserin|Mirtazapin|mirtazapine|Mirtazapine (substance)|Product containing mirtazapine (medicinal product)|1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine|MIRTAZAPINE | mirtazapine |
C0599473 | null | enantiomer|enantiomers | enantiomer |
C0234194 | Sensing of noxious mechanical, thermal or chemical stimuli by NOCICEPTORS. It is the sensory component of visceral and tissue pain (NOCICEPTIVE PAIN). | nociception|Nociperceptions|nociceptions|Nociperception|Nociceptions|Nociception | Nociception |
C0677040 | The study of the spatial groups that affect the properties of atoms within molecules. | STEREOCHEMISTRY|stereochemistry|Stereochemistry | Stereochemistry (discipline) |
C0011892 | A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) | (5α,6α)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate (ester)|DIAMORPHINE|Black tar|Diacetylmorphine|Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, diacetate (ester)|acetomorphine|Product containing diamorphine (medicinal product)|Acetomorphine|Diamorphine|diacetylmorphine|Diamorphine (substance)|Diamorphine-containing product|heroin|7,8-Dihydro-4,5-alpha-epoxy-17-methylmorphinan-3,6-alpha-diol diacetate|diamorphine|Heroin|heroin products|H|Skag|Smack|Junk|O,O'-Diacetylmorphine|3,6-Diacetylmorphine | heroin |
C0039536 | An agent that causes the production of physical defects in the developing embryo. | teratogens|Teratogenic substance, NOS|Teratogens|teratogen|Teratogen|Teratogenic Substances|Teratogen (substance)|Teratogenic substance | Teratogens |
C0028040 | Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. | (S)-3-(1-methylpyrrolidin-2-yl)pyridine|nicotine product|Product containing nicotine (medicinal product)|beta-Pyridyl-alpha-N-methylpyrrolidine|nicotine in any form|(S)-3-(1-Methyl-2-pyrrolidinyl)pyridine|(S)-(-)-nicotine|Nicotina|NIC|(-)-Nicotine|(S)-3-(N-methylpyrrolidin-2-yl)pyridine|1-Methyl-2-(3-pyridyl)pyrrolidine|(S)-Nicotine|Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-|Nicotine (substance)|Nicotine|beta-pyridyl-alpha-N-methylpyrrolidine|Nikotyna|1-methyl-2-(3-pyridyl)pyrrolidine|Nikotin|3-(2-(N-methylpyrrolidinyl))pyridine|nicotine|NICOTINE|3-(N-methylpyrollidino)pyridine|L(-)-nicotine|Nicotine-containing product|(S)-3-(1-methyl-2-pyrrolidinyl)pyridine|(-)-nicotine | nicotine |
C0169911 | null | messengers|messenger|messenger protein | messenger protein |
C0028040 | Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. | (S)-3-(1-methylpyrrolidin-2-yl)pyridine|nicotine product|Product containing nicotine (medicinal product)|beta-Pyridyl-alpha-N-methylpyrrolidine|nicotine in any form|(S)-3-(1-Methyl-2-pyrrolidinyl)pyridine|(S)-(-)-nicotine|Nicotina|NIC|(-)-Nicotine|(S)-3-(N-methylpyrrolidin-2-yl)pyridine|1-Methyl-2-(3-pyridyl)pyrrolidine|(S)-Nicotine|Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-|Nicotine (substance)|Nicotine|beta-pyridyl-alpha-N-methylpyrrolidine|Nikotyna|1-methyl-2-(3-pyridyl)pyrrolidine|Nikotin|3-(2-(N-methylpyrrolidinyl))pyridine|nicotine|NICOTINE|3-(N-methylpyrollidino)pyridine|L(-)-nicotine|Nicotine-containing product|(S)-3-(1-methyl-2-pyrrolidinyl)pyridine|(-)-nicotine | nicotine |
C0045137 | null | GU-17|6'-deoxychalcone|2',4',4-trihydroxychalcone|GU 17 | isoliquiritigenin |
C0018338 | Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) | guanosine 3'5' monophosphate|Guanosine Cyclic 3',5' Monophosphate|Guanosine Cyclic 3',5'-Monophosphate|Monophosphate, Guanosine Cyclic|Cyclic guanosine monophosphate|Guanosine, cyclic 3',5'-(hydrogen phosphate)|cyclic guanosine monophosphate (cGMP)|cgmp|Cyclic GMP|Guanosine Cyclic Monophosphate|cGMP|Cyclic guanosine monophosphate (substance)|cyclic GMP|Guanosine Cyclic-3',5'-Monophosphate|Cyclic-3',5'-Monophosphate, Guanosine|Cyclic 3',5'-Monophosphate, Guanosine|CYCLIC GMP|cyclic gmp|Cyclic Monophosphate, Guanosine|cyclic guanosine monophosphate|cyclic 3',5'-guanosine monophosphate|GMP, Cyclic|Guanosine Cyclic 3',5'-(Hydrogen Phosphate)|Guanosine Cyclic 3,5 Monophosphate|3',5'-Monophosphate, Guanosine Cyclic | Cyclic GMP |
C0699857 | the anion and oxidizing agent NO3-. | nitrate | Nitrate |
C0027908 | Endogenous signaling molecules secreted by neurons that alter the behavior of neurons or effector cells. Neurotransmitter is used here in its most general sense, including not only messengers that act directly to regulate ion channels, but also those that act through second messenger systems, and those that act at a distance from their site of release. Included are neuromodulators, neuroregulators, neuromediators, neurohormones, and neurohumors, whether or not acting at synapses. | Neurotransmitter (substance)|Neurotransmitters|Neurotransmitter|Substances, Nerve Transmitter|Transmitter Substances, Nerve|Neurotransmitter, NOS|Nerve Transmitter Substances|neurotransmitters|neurotransmitter | Neurotransmitters |
C0025242 | AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. | memantine|Product containing memantine (medicinal product)|Memantine (substance)|3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine|Memantin|3,5-Dimethyl-1-adamantanamine|Memantine-containing product|Memantinum|Tricyclo(3.3.1.13,7)decan-1-amine, 3,5-dimethyl-|1,3-Dimethyl-5-adamantanamine|memantin|Memantine|1-Amino-3,5-dimethyladamantane|Memantina|3,5-Dimethyl-1-aminoadamantane|1,3-Dimethyl-5-aminoadamantane|MEMANTINE | memantine |
C0527316 | The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity. This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases. | Product containing donepezil (medicinal product)|1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-|donepezil|Domepezil|Donepezil-containing product|Donepezilo|Donepezilum|DONEPEZIL|Donepezil|Donepezil (substance) | donepezil |
C0016967 | A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. | galanthamine|Galantamina|Galantamine|galantamin|Lycoremine|Galantamin|Galantamine (substance)|lycoremine|GALANTAMINE|Product containing galantamine (medicinal product)|galantamine|Galantamine-containing product|6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-|Galanthamine|(-)-Galanthamine | galantamine |
C0649350 | A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE. | RIVASTIGMINE|Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)|Rivastigmina|(S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate|Rivastigmine|rivastigmine|Product containing rivastigmine (medicinal product)|M-((S)-1-(Dimethylamino)ethyl)phenyl Ethylmethylcarbamate|Rivastigmine-containing product|(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate|Rivastigmine (substance)|m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate | rivastigmine |
C0008425 | Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. | Anticholinesterases|Anticholinesterase Agents|cholinesterase inhibitor|Cholinesterase Inhibitors|Anticholinesterase Drugs|Anti-Cholinesterases|Drugs, Anticholinesterase|Anti Cholinesterases|Agents, Anticholinesterase|Cholinesterase inhibitor drug|Anticholinesterase|Anticholinesterase drug, NOS|anticholinesterase|anticholinesterases|cholinesterase inhibitors|anti cholinesterase|Cholinesterase Inhibitor|Cholinesterase inhibitors|Anticholinesterase parasympathomimetics|Inhibitors, Cholinesterase | Cholinesterase Inhibitors |
C0871189 | null | psychotics symptoms|Psychotic symptom (observable entity)|psychotic symptoms | Psychotic symptom |
C0527315 | null | Aricept|aricept | Aricept |
C0521119 | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. [GOC:go_curators] | extracellular region|extracellular|Extracellular (qualifier value)|Extracellular | Extracellular |
C0036751 | A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. | 1H-Indol-5-ol, 3-(2-aminoethyl)-|Serotonin|5-Hydroxy tryptamine|5-ht|5-HT|SEROTONIN|5ht|Serotonin (substance)|5 hydroxytryptamine|Hippophaine|5 ht|5-HT - 5-hydroxytryptamine|serotonins|thrombocytin|5-hydroxytryptamine|sérotonine|5-Hydroxytryptamine|5-hydroxy tryptamine|5 Hydroxytryptamine|thrombotonin|5HT|serotonin|3-(2-Aminoethyl)-1H-indol-5-ol|Enteramine|5 hydroxy tryptamine | serotonin |
C0870883 | A substance made or used when the body breaks down food, drugs or chemicals, or its own tissue (for example, fat or muscle tissue). This process, called metabolism, makes energy and the materials needed for growth, reproduction, and maintaining health. It also helps get rid of toxic substances. | Metabolites|metabolite|Metabolite (substance)|metabolites|Metabolite | Metabolite |
C0028633 | Collection of pleomorphic cells in the caudal part of the anterior horn of the LATERAL VENTRICLE, in the region of the OLFACTORY TUBERCLE, lying between the head of the CAUDATE NUCLEUS and the ANTERIOR PERFORATED SUBSTANCE. It is part of the so-called VENTRAL STRIATUM, a composite structure considered part of the BASAL GANGLIA. | Accumbens, Nucleus|Accumbens nucleus|Nucleus, Accumbens|Nucleus accumbens (body structure)|Colliculus of caudate nucleus|Nucleus accumbens|accumbens nucleus|Septi, Nucleus Accumbens|NUCLEUS ACCUMBENS|Nucleus accumbens septi|Accumbens Nucleus|Accumbens Septus, Nucleus|Nucleus Accumbens|nucleus accumbens|Accumbens Septi, Nucleus|Colliculus nuclei caudati|Nucleus Accumbens Septus|Septus, Nucleus Accumbens|Nucleus Accumbens Septi | Nucleus Accumbens |
C0175405 | A region in the MESENCEPHALON which is dorsomedial to the SUBSTANTIA NIGRA and ventral to the RED NUCLEUS. The mesocortical and mesolimbic dopaminergic systems originate here, including an important projection to the NUCLEUS ACCUMBENS. Overactivity of the cells in this area has been suspected to contribute to the positive symptoms of SCHIZOPHRENIA. | Area tegmentalis ventralis|Area Tegmentalis Ventralis|Ventral tegmental nucleus of Tsai|Ventral tegmental area of Tsai|Area Tegmentalis Ventrali|Ventral tegmental area|Tegmentalis Ventrali, Area|Ventral Tegmental Area of Tsai|Tegmentalis Ventralis, Area|VTA|vta|ventral tegmental area|Tegmental Area, Ventral|A10a|Ventral tegmental nucleus (Tsai) | Ventral Tegmental Area |
C1278935 | null | Entire descending thoracic aorta (body structure)|Entire descending thoracic aorta | Entire descending thoracic aorta |
C0230168 | The region in the abdomen extending from the thoracic DIAPHRAGM to the plane of the superior pelvic aperture (pelvic inlet). The abdominal cavity contains the PERITONEUM and abdominal VISCERA, as well as the extraperitoneal space which includes the RETROPERITONEAL SPACE. | Abdomen|intraabdominal|abdomen|Cavitas abdominis|abdominal cavity|Space of abdominal compartment|Cavity of abdominal compartment|Cavities, Abdominal|BODY CAVITY, ABDOMINAL|Abdominal Cavity|Abdominal cavity|Cavitas abdominalis|ABDOMINAL CAVITY|abdominal cavities|Intraabdominal|Cavity of compartment of abdomen|Abdominal cavity, NOS|Cavity, Abdominal|Abdominal Cavities | Abdominal Cavity |
C0524865 | Procedures used to reconstruct, restore, or improve defective, damaged, or missing structures. | Plastic repair with reconstruction|Plastic repair, reconstruction|reconstructive surgery|Surgical reconstruction, NOS|reconstructions|Surgical Procedure, Reconstructive|Procedure, Reconstructive Surgical|Reconstructive Surgical Procedures|Reconstructive Surgery|Procedures, Reconstructive Surgical|reconstruction action|Reconstruction - action (qualifier value)|surgical reconstruction|Surgery, Reconstructive|Surgical Procedures, Reconstructive|Reconstruction|Reconstructive Surgeries|Reconstruction procedure|Reconstructive Surgical Procedure|Surgeries, Reconstructive|Reconstruction procedure (procedure)|reconstruction|surgical reconstruction procedure|Reconstruction - action | Reconstructive Surgical Procedures |
C0225968 | The outer membranous connective tissue layer of the heart tissue. | Visceral layer of serous pericardium|Visceral serous pericardium of heart|Pericardium, Visceral|Visceral serous pericardium|EPICARDIUM|Structure of visceral pericardium (body structure)|epicardium|Visceral serous pericardium proper|Visceral pericardium|Lamina visceralis (epicardium)|visceral pericardium|Epicardium|Visceral Pericardium|Structure of visceral pericardium | Epicardium |
C1522460 | The portion of the descending aorta proceeding from the arch of the aorta and extending to the DIAPHRAGM, eventually connecting to the ABDOMINAL AORTA. | Pars thoracica aortae|Descending thoracic aorta|aorta thoracic|Thoracic aorta structure|Thoracic aorta, NOS|Aorta, Thoracic|Thoracic aorta structure (body structure)|THORACIC AORTA|Thoracic part of aorta|Thoracic Aorta|Aorta thoracica|Thoracic aorta|thoracic aorta | Thoracic aorta |
C0206054 | Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues using a transducer placed in the esophagus. | Echocardiography, Transesophageal|Transoesophageal echocardiogram|Transoesophageal echocardiography|TOE - Transoesophageal echocardiography|echocardiograms transesophageal|transesophageal echocardiography|Transesophageal Echocardiography|Transesophageal echocardiography (procedure)|TOE - Transesophageal echocardiography|Transesophageal echocardiography|Transesophageal echocardiogram|transesophageal echocardiogram|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|TEE|TEE procedure | Echocardiography, Transesophageal |
C0004398 | Postmortem examination of the body. | necropsy|Autopsy examination|Necropsy|Post Mortem Examination|Examinations, Post-Mortem|AUTOPSY|Autopsy|postmortem|PM - Postmortem examination|Necropsy, NOS|Postmortem Examinations|Postmortem Examination|autopsy|Post-Mortem Examination|postmortem examination|Post-Mortem Examinations|Postmortem examination (procedure)|Examination, Postmortem|Autopsy examination (procedure)|Postmortem examination|Autopsies|Autopsy examination, NOS|Autopsy, NOS|Examinations, Postmortem|Examination, Post-Mortem | Autopsy |
C0008546 | The material of CHROMOSOMES. It is a complex of DNA; HISTONES; and nonhistone proteins (CHROMOSOMAL PROTEINS, NON-HISTONE) found within the nucleus of a cell. | Chromatin (substance)|Chromatin, NOS|Chromatins|Karyoplasm|chromoplasm|chromatin|Chromatin|Nuclear sap | Chromatin |
C0002312 | A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted. | Thalassemia-alpha|alpha-thalassaemia|Alpha Thalassemia|alpha thalassaemia|alpha-Thalassemias|Thalassemia, Alpha|Alpha thalassaemia syndrome|thalassemia alpha|alpha-thalassemia|alpha-Thalassemia|ALPHA-THALASSEMIA|Alpha-thalassemia|Haemoglobin H disease|alpha thalassemia|Alpha thalassemia|alpha thalassemias|A-Thalassemia|Alpha thalassaemia|Hemoglobin H Disease|Thalassemia alpha|alpha Thalassemia|Hemoglobin H disease|alpha Thalassemia, NOS|Disease, Hemoglobin H|Alpha thalassemia (disorder)|Alpha thalassemia syndrome | alpha-Thalassemia |
C0850715 | An abnormality of the hematopoietic system. [HPO:probinson] | Abnormality of the haematopoietic system|Abnormality of the hematopoietic system|Abnormality of blood and blood-forming tissues | Abnormality of blood and blood-forming tissues |
C0443781 | null | Globin chain (substance) | Globin chain |
C0040845 | An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). | all trans Retinoic Acid|all-trans-retinoic acid|Acid, Retinoic|3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|Vitamin A acid, all-trans-|Product containing tretinoin (medicinal product)|trans Retinoic Acid|Trans Retinoic Acid|Vitamin A Acid|all-trans-beta-Retinoic acid|Acid, trans-Retinoic|vitamin a acid|all-trans-Vitamin A1 acid|All-trans Vitamin A Acid|2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-|beta-retinoic acid|TRA|all trans Retinoic acid|retinoic acid|Retinoic Acid|Acide retinoique|(All-E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|Tretinoin-containing product|Tretinoin (substance)|all-trans-Tretinoin|trans-Retinoic Acid|All-trans Retinoic Acid|Tretinoin|beta-Retinoic Acid|Retinoic acid|trans retinoic acid|(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|tretinoin|all-trans retinoic acid|all-trans-Retinoic acid|TRETINOIN|Acid, Vitamin A|tretinoinum|Tretinoina|Tretinoinum|all-(E)-Retinoic acid|all-trans vitamin A acid|Vitamin A acid|Trétinone|trans vitamin A acid|all-trans-Retinoic Acid|all trans retinoic acid|all trans-Retinoic acid|vitamin A acid|ATRA|Trans Vitamin A Acid|beta-Retinoic acid|all-trans-Vitamin A acid|trans-Retinoic acid|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)|Acid, all-trans-Retinoic|Tretin M|Retionic acid|(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid | tretinoin |
C0023434 | A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. | Lymphomas, Small-Cell|B-cell CLL|Lymphocytic Leukemia, Chronic, B-Cell|Leukemias, Chronic B-Lymphocytic|Lymphomas, CLL Lymphoplasmacytoid|Lymphoma, Lymphocytic, Diffuse, Well Differentiated|chronic lymphatic leukemia|Chronic B-Cell Leukemia|Lymphoma, Lymphocytic, Diffuse, Well-Differentiated|Small-Cell Lymphomas|Well-Differentiated Lymphocytic Lymphomas|LEUKEMIA, CHRONIC LYMPHOCYTIC|CLL Lymphoplasmacytoid Lymphoma|Lymphocytic Leukemias, Chronic|LEUKEMIA, LYMPHOCYTIC, CHRONIC|cll chronic lymphocytic leukemia|chronic leukemia lymphocytic|Lymphoid leukemia, chronic|Leukemias, Chronic B-Cell|B Cell CLL|B-Cell Leukemias, Chronic|Leukemia, Chronic B-Cell|b-cell cll|Chronic B-Lymphocytic Leukemias|Leukemia, Chronic Lymphatic|chronic lymphatic leukaemia|chronic lymphocytic leukemia (cll)|Lymphocytic lymphoma|Lymphomas, Small Lymphocytic|CLL Lymphoplasmacytoid Lymphomas|Lymphocytic Lymphomas|B-Cell Chronic Lymphoid Leukemia|Chronic B-Lymphocytic Leukemia|Lymphoblastic Leukemias, Chronic|B-cell chronic lymphocytic leukemia|Chronic lymphocytic leukemia|Chronic Lymphocytic Leukemia (CLL)|Chronic B-Cell Lymphocytic Leukemia|lymphocytic leukemia chronic|Chronic Lymphoblastic Leukemia|Leukemia, Lymphocytic, Chronic|LEUKEMIA LYMPHOCYTIC CHRONIC|Lymphoplasmacytoid Lymphoma, CLL|BCLL|Chronic lymphoid leukemia|B Cell Leukemia, Chronic|B-Lymphocytic Leukemia, Chronic|Lymphomas, Well-Differentiated Lymphocytic|Chronic Lymphogenous Leukemia|Chronic lymphoid leukaemia, disease|LEUKEMIA CHRONIC LYMPHOCYTIC|chronic lymphocytic leukemia|Chronic lymphocytic leukaemia|chronic lymphoblastic leukemia|Chronic lymphoid leukemia, disease|B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (morphologic abnormality)|Lymphocytic Lymphoma, Diffuse, Well-Differentiated|Lymphocytic Lymphoma, Well-Differentiated|Small Lymphocytic Lymphoma|lymphocytic leukemia, chronic|b chronic lymphocytic leukemia|CLL - Chronic lymphocytic leukaemia|Leukemia, Chronic Lymphocytic, B-Cell|B-Cell Chronic Lymphogenous Leukemia|B-Cell Chronic Lymphocytic Leukemia|Leukemia, Chronic B-Lymphocytic|Lymphoma, Lymphocytic|Chronic lymphocytic leukemia, NOS|Chronic lymphocytic leukemia, B-cell type|Chronic B-Cell Leukemias|Lymphoma, CLL Lymphoplasmacytoid|Lymphocytic Lymphomas, Small|Lymphoma, Small Lymphocytic|Small Lymphocytic Lymphomas|Lymphocytic Lymphomas, Well-Differentiated|Chronic lymphatic leukemia|Lymphoma, Small-Cell|Leukemia, chronic lymphocytic (CLL)|Lymphoma, Lymphocytic, Well-Differentiated|Leukemias, Chronic Lymphoblastic|Lymphomas, Lymphocytic|B-Cell CLL|Chronic Lymphocytic Leukemia|CLL|Lymphoma, Small Cell|B Lymphocytic Leukemia, Chronic|Lymphocytic Leukemia, Chronic, B Cell|LEUKEMIA, CHRONIC LYMPHATIC|Leukemia, B Cell, Chronic|Chronic lymphocytic leukaemia, B-cell type|b cell leukemia|Chronic lymphoid leukaemia|chronic lymphoid leukemia|b cell lymphocytic leukemia|Diffuse Well-Differentiated Lymphocytic Lymphoma|leukemia, B-cell chronic lymphocytic|B-cell chronic lymphocytic leukaemia|B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma|Lymphoma, Well-Differentiated Lymphocytic|B-CLL - B-cell chronic lymphocytic leukaemia|Chronic lymphoid leukemia, disease (disorder)|Disrupted In B-Cell Malignancy|B Cell Lymphocytic Leukemia|Diffuse Well Differentiated Lymphocytic Lymphoma|clls|Lymphoma, Lymphoplasmacytoid, CLL|Lymphoma, Lymphocytic, Well Differentiated|Leukemia, Chronic Lymphocytic|B-CLL - B-cell chronic lymphocytic leukemia|CLL - Chronic lymphocytic leukemia|b-cell leukemia|Lymphocytic Lymphoma, Small|Lymphoplasmacytoid Lymphomas, CLL|Lymphocytic Lymphoma|B-Lymphocytic Leukemias, Chronic|Chronic lymphatic leukaemia|Leukemia, Lymphocytic, Chronic, B-Cell|B-Cell Malignancy, Low-Grade|chronic lymphogenous leukemia|cll|Small Cell Lymphoma|Lymphocytic Lymphoma, Diffuse, Well Differentiated|Lymphocytic Lymphoma, Well Differentiated|chronic lymphocytic leukaemia|B-Cell Lymphocytic Leukemia|Chronic Lymphoblastic Leukemias|chronic lymphocytic leukemia, B-cell|Well-Differentiated Lymphocytic Lymphoma|Leukemia, Lymphoblastic, Chronic|CLL, B-cell|Lymphoma, Small Lymphocytic, Plasmacytoid|B-cell chronic lymphocytic leukemia (disorder)|leukemia, chronic lymphocytic|Small-Cell Lymphoma|B cell chronic lymphocytic leukemia|B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma|lymphocytic leukemia, B-cell chronic|Leukemia, B-Cell, Chronic|Chronic Lymphatic Leukemia|Lymphoblastic Leukemia, Chronic|leukemia chronic lymphocytic|B Cell Chronic Lymphocytic Leukemia|Hematopoeitic - Chronic Lymphocytic Leukemia (CLL)|B-Cell Leukemia, Chronic|CHRONIC LYMPHOCYTIC LEUKEMIA|Lymphocytic Leukemia, Chronic|leukemia b cell|Leukemia, Lymphocytic, Chronic, B Cell|Chronic Lymphocytic Leukemias | Chronic Lymphocytic Leukemia |
C0059985 | A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. (NCI04) | fludarabine|9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine|Fludarabine (substance)|Fludarabinum|9-Beta-D-arabinofuranosyl-2-fluoroadenine|FLUDARABINE|9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-|Fludarabina|Fludarabine-containing product|F Ara A|2-fluoro ARA-A|2-Fluorovidarabine|9-beta-D-arabinofuranosyl-2-fluoroadenine|Fludarabine|F-ara-A|2-F-ARAA|2-Fluoro-9-beta-arabinofuranosyladenine|2-fluoroadenine arabinoside|Product containing fludarabine (medicinal product) | fludarabine |
C0059985 | A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. (NCI04) | fludarabine|9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine|Fludarabine (substance)|Fludarabinum|9-Beta-D-arabinofuranosyl-2-fluoroadenine|FLUDARABINE|9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-|Fludarabina|Fludarabine-containing product|F Ara A|2-fluoro ARA-A|2-Fluorovidarabine|9-beta-D-arabinofuranosyl-2-fluoroadenine|Fludarabine|F-ara-A|2-F-ARAA|2-Fluoro-9-beta-arabinofuranosyladenine|2-fluoroadenine arabinoside|Product containing fludarabine (medicinal product) | fludarabine |
C1517908 | null | DepoCyte | DepoCyte |
C1517908 | null | DepoCyte | DepoCyte |
C0085669 | A rapidly progressing cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of white blood cells to be produced and enter the blood stream. | acute leukemias|stem cell acute leukemia|acute leukemia not otherwise specified|Acute leukemia, disease (disorder)|Acute leukaemia|leukemia, acute|Acute leukaemia, morphology, including blast cell OR undifferentiated leukaemia|Acute leukemia, NOS|Acute leukemia, disease|acute leukemia, NOS|LEUKEMIA ACUTE|Leukemia of unspecified cell type, acute|Acute leukemia NOS|acute leukemia|acute leukaemias|acute leukaemia|Acute leukemia|Acute leukemia, morphology, including blast cell OR undifferentiated leukemia|ACUTE LEUKEMIA|LEUKAEMIA ACUTE|Acute leukemia, morphology, including blast cell OR undifferentiated leukemia (morphologic abnormality)|Acute leukaemia, NOS|Acute Leukemia|Acute leukaemia, disease|Acute leukemias | Acute leukemia |
C0279130 | null | Central nervous system (CNS) metastases|Central nervous system metastases (tumor staging)|Central nervous system metastases|CNS metastases | Central nervous system (CNS) metastases (tumor staging) |
C0010711 | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) | 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone|1.beta.-D-Arabinofuranosylcytosine|2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-|Cytosine-beta-arabinoside|2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-|Arabinosylcytosine|Cytosine arabinoside|Cytarabinum|cytarabinum|4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone|Cytosine-.beta.-arabinoside|Citarabina|arabinofuranosylcytosine|Cytosine Arabinoside|1-.beta.-D-Arabinofuranosylcytosine|Cytarabine|1-beta-D-Arabinofuranosylcytosine|aracytidine|Arabinofuranosylcytosine|Cytosine-1-beta-D-arabinofuranoside|Beta-cytosine Arabinoside|cytosine arabinoside|Arabinoside, Cytosine|Beta-Cytosine Arabinoside|2(1H)-pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-|1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone|Product containing cytarabine (medicinal product)|cytosine-.beta.-arabinoside|Cytarabine-containing product|cytarabine|1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone|beta-cytosine arabinoside|CYTARABINE|arabinosylcytosine|1.beta.-D-arabinofuranosylcytosine|Cytarabine (substance)|Aracytidine|1-beta-D-arabinofuranosylcytosine|1-Beta-D-arabinofuranosylcytosine|cytosine-β-D-arabinofuranoside|1-.beta.-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone|2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-|.beta.-Cytosine arabinoside | cytarabine |
C0042425 | A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla. | Biliaropancreatic ampulla|ampulla hepatopancreatic|Ampulla biliaropancreatica|Cholangiopancreatic duct|Ampullas, Hepatopancreatic|ampulla hepatopancreatica|ampulla vater's|Hepatopancreatic Ampullas|Ampulla, Hepatopancreatic|ampulla of vater|hepatopancreatic ampulla|Ampulla of bile duct|Vater's Ampulla|vater's ampulla|Ampulla of Vater|Ampulla, Vater's|Vaters Ampulla|Hepatopancreatic ampulla|Hepatopancreatic Ampulla|ampulla of Vater|Ampulla hepatopancreatica|Structure of ampulla of Vater|Ampulla|Structure of ampulla of Vater (body structure)|Vater Ampulla | Ampulla of Vater |
C0017351 | This region represents the germline organization of the immunoglobulin heavy chain locus. The locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink) | IGH gene|Immunoglobulin Heavy Chain Locus|IGH|Immunoglobulin Heavy Gene|immunoglobulin heavy locus|Immunoglobulin gene GM allotype (substance)|Immunoglobulin gene GM allotype|Immunoglobulin heavy chain gene|Immunoglobulin Heavy Chain Genes|immunoglobulin heavy chain locus|Immunoglobulin Heavy Locus|Ig Heavy Chain Genes|Immunoglobulin Heavy Chain Gene|IgH locus|Genes, Immunoglobulin Heavy Chain | IGH gene |
C0033053 | Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth. | Diagnoses, Intrauterine|Diagnosis, Antenatal|antenatal diagnosis|Intrauterine Diagnosis|Diagnoses, Prenatal|antepartum diagnosis|Intrauterine Diagnoses|diagnosis prenatal|Diagnosis, Prenatal|Prenatal Diagnoses|Prenatal diagnosis|Antenatal Diagnoses|Prenatal Diagnosis|Antenatal Diagnosis|Diagnosis, Intrauterine|prenatal diagnosis|Diagnoses, Antenatal | Prenatal Diagnosis technique |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.